Zoster Vaccination Pearls
Rx Shorts: With 2 shingles vaccines available, questions continue to multiply. Take away 4 small pearls to help answer patient questions and yours.
Shingles is becoming less common in both adults and children in the U.S., according to results from a database study.Reuters Health Information
(MedPage Today) -- Vaccine development may help with prevention of herpes zoster in this population
This report evaluates the fifth year of the shingles vaccination programme in England from 2017 to 2018.
hon Varicella-zoster virus (VZV) is a pathogenic human herpes virus that causes varicella (chickenpox) as a primary infection, following which it becomes latent in peripheral ganglia. Decades later, the virus may reactivate either spontaneously or after a number of triggering factors to cause herpes zoster (shingles). Varicella and its complications are more severe in the immunosuppressed. The most frequent and important complication of VZV reactivation is postherpetic neuralgia, the cause of which is unknown and for which treatment is usually ineffective. Reactivation of VZV may also cause a wide variety of neurologic...
AbstractThe herpes zoster (shingles) vaccine is recommended for all adults aged ≥ 60 years without contraindications to prevent shingles and post-herpetic neuralgia. There are no published studies on zoster vaccination rates, barriers, or workflows in adults who have experienced homelessness. Due to barriers specific to this vaccine, including difficulty determining insura nce coverage, high upfront costs, need for storage in a freezer, and under-prescription by physicians, uptake is lower compared to other recommended vaccines for older adults. To address these barriers, we developed a new approach of partn...
Gelatine is added as a stabiliser to prevent vaccines degrading in transportation. In the UK, the worst offenders are the nasal flu vaccine Fluenz Tetra, the shingles jab Zostavax and the MMR.
The newer shingles vaccine Shingrix was far more successful in preventing the condition compared with the older vaccine Zostavax among patients 50 and older.
(St. Michael's Hospital) A systematic review of clinical studies involving more than two million patients aged 50 years and older suggests the newer shingles vaccine Shingrix was far more successful in preventing the painful condition compared to the older vaccine Zostavax.
(Natural News) In the 1980s, after a series of very serious lawsuits against vaccine companies from healthcare providers due to vaccine injuries, the CDC, in cahoots with vaccine manufacturers, created the Vaccine Injury Compensation Program (VICP) so that no vaccine maker could ever be sued again. From that date forward, if any U.S. person was...
PMID: 30277735 [PubMed - in process]